Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Panel Says Small Public Firms Should Be Exempt From External Auditing Law

This article was originally published in The Gray Sheet

Executive Summary

A Securities & Exchange Commission committee voiced approval for changes to the Sarbanes-Oxley Act that could save small device firms millions of dollars spent to comply with external auditing requirements

You may also be interested in...



Sarbanes-Oxley exemption

AdvaMed and the Medical Device Manufacturer's Association join a coalition of technology associations in an April 3 letter urging the Securities and Exchange Commission to adopt a draft guidance that would ease external auditing requirements for public companies with annual fiscal revenues under $250 mil. The letter states that "this approach will begin to address the disproportionate cost burdens of section 404 requirements that continue to hamper smaller companies' ability to invest in research and development, to gain access to public capital markets, and to remain competitive." Since it was enacted in 2002, the Sarbanes-Oxley Act has required all public companies to pay to have their internal controls checked by an external auditor (1"The Gray Sheet" Dec. 19, 2005, p. 11)...

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023039

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel